Reviews/TNF Alpha Inhibitors/TNF-alpha inhibitors achieve PASI 75 response in moderate-to-severe plaque psoriasis
· TN-PSO-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This claim asks whether TNF-alpha inhibitors, a class of psoriasis drugs, get patients to PASI 75, meaning a 75% improvement in skin disease. A large placebo-controlled trial of adalimumab found 71% of treated patients reached that mark versus 7% on placebo [4], and other studies across different designs pointed the same way [5][7][3][11][10]. The strongest, most rigorous evidence is all for one drug, adalimumab, while the other two drugs in the class rest on smaller, non-randomised data [10][9]. Response rates also varied a lot between drugs and studies, from roughly four in ten patients to nearly all of them [10]. The panel accepted that TNF inhibitors do achieve PASI 75 but noted the class-level reading leans heavily on adalimumab and includes some arthritis and paediatric populations rather than adult plaque psoriasis alone.
The corpus directly and repeatedly measures PASI 75 achievement by TNF inhibitors in moderate-to-severe plaque psoriasis. The anchor is a 1212-patient placebo-controlled phase 3 RCT in which 71% (578 of 814) of adalimumab-treated patients versus 7% (26 of 398) on placebo reached PASI 75 at week 16 [4], corroborated by an adalimumab equivalence RCT reporting 60.34% and 63.37% [5] and a REVEAL subgroup analysis showing consistent 75% or greater improvement across patient subgroups [7]. A paediatric RCT reported PASI 75 in 58% on adalimumab 0.8 mg/kg versus 32% on methotrexate [3], and a target-trial-emulation cohort reported 52.0% at one year [11]. A single non-randomised study of all three agents reported week-16 PASI 75 of 41% for etanercept, 52% for adalimumab and 96% for infliximab (63% overall, N=81) [10], and the BioCAPTURE registry found a higher chance of PASI 75 with adalimumab than etanercept at one year [9]. The contested point: The claim is class-level, but placebo-controlled RCT-grade evidence exists only for adalimumab [4][5][7]; etanercept and infliximab PASI 75 data come solely from one N=81 non-randomised study [10] and registry or switch cohorts [9][12], with etanercept underperforming (41% in [10]; lower PASI 75 chance than adalimumab in [9]). Several contributory sources are also population-indirect, being psoriatic-arthritis cohorts [6][8] or paediatric [3] rather than adult plaque psoriasis.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from TNF Alpha Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim is class-level ('TNF-alpha inhibitors') but the only placebo-controlled RCT-grade evidence is adalimumab [4][5][7]; etanercept and infliximab PASI75 data come solely from one N=81 non-randomised study [10] and registry/switch cohorts [9][12]. Etanercept underperforms (41% in [10]; lower PASI75 chance than adalimumab in [9]).
Population indirectness: [6] and [8] are psoriatic-arthritis cohorts with concomitant psoriasis and [3] is paediatric, none being an adult plaque-psoriasis cohort; [6] moreover reports PASI100 (23.8%), not PASI75. These add little weight to the exact claim wording.
Where it remains uncertain. The class claim rests disproportionately on adalimumab; etanercept and infliximab come only from one N=81 non-randomised study [10] and registry or switch cohorts [9][12], with etanercept the weakest (41% in [10]).
Aleatory
PASI 75 is a per-patient binary outcome and only a proportion of patients reach it in any study (e.g. 71% in [4], 52% in [11]), reflecting inherent variation in who responds.
Epistemic
Their PASI 75 data come only from one N=81 non-randomised study [10] and registry or switch cohorts [9][12]; a head-to-head or placebo-controlled trial could resolve their true class contribution.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT PASI75 benefit of adalimumab over methotrexate, extending to paediatric severe plaque psoriasis
“At week 16, PASI75 was achieved in 22 (58%) of 38 patients in the adalimumab 0·8 mg/kg group compared with 12 (32%) of 37 patients in the methotrexate group (p=0·027).”
Panel auditInternal validity: high · scope of inference: Children and adolescents with severe plaque psoriasis, adalimumab vs methotrexate.Key limitations: pediatric population · comparator is methotrexate not placebo · severe (not moderate-to-severe) cohort
Placebo-controlled phase 3 RCT establishing the PASI75 effect of a TNFi (adalimumab) in adult moderate-to-severe psoriasis
“At week 16, 71% (578 of 814) of adalimumab- and 7% (26 of 398) of placebo-treated patients achieved greater than or equal to 75% improvement in the PASI score.”
Panel auditInternal validity: high · scope of inference: Adults with moderate-to-severe chronic plaque psoriasis, adalimumab vs placebo.Key limitations: no p-value stated for PASI 75 contrast · no active comparator
Independent RCT confirming ~63% PASI75 with adalimumab at week 16
“At week 16 PASI 75 was achieved by 60.34% and 63.37% of patients in BCD-057 and iADA arms, respectively (p = 0.5622).”
Panel auditInternal validity: high · scope of inference: Adults with moderate-to-severe plaque psoriasis, biosimilar vs innovator adalimumab.Key limitations: no placebo arm · both arms are the same TNFi
The abstract gives adalimumab's PASI 100 rate (23.8%) but no PASI 75 figure, so the claim's threshold is not reported.
Panel auditInternal validity: high · scope of inference: PsA patients with concomitant moderate-to-severe plaque psoriasis, secukinumab vs adalimumab.Key limitations: outcome is PASI 100 not PASI 75 · PsA subgroup · prespecified subanalysis
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple primary studies, anchored by a large placebo-controlled RCT, directly demonstrate TNF inhibitors achieving PASI 75 in moderate-to-severe plaque psoriasis, with discount for adalimumab-weighted class evidence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-controlled RCTs for etanercept and infliximab. The class claim leans on adalimumab; etanercept and infliximab PASI 75 rests only on one non-randomised study [10] and cohorts [9][12]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Randomised, placebo-controlled phase 3 trials of etanercept and infliximab in adult moderate-to-severe plaque psoriasis reporting week-16 PASI 75.
Open question: Do etanercept and infliximab achieve PASI 75 at rates demonstrated under randomised, placebo-controlled conditions in adult plaque psoriasis? Why it is still open: Their only direct PASI 75 data here is a single N=81 non-randomised study [10] plus registry and switch cohorts [9][12].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19